Goldman Sachs Group Inc. Grows Stock Position in Insulet Corporation $PODD

Goldman Sachs Group Inc. increased its position in Insulet Corporation (NASDAQ:PODD) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 768,066 shares of the medical instruments supplier’s stock after acquiring an additional 10,254 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Insulet were worth $218,315,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its holdings in Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after acquiring an additional 142,922 shares in the last quarter. ING Groep NV increased its holdings in Insulet by 88.5% in the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock worth $5,341,000 after acquiring an additional 8,123 shares in the last quarter. Jain Global LLC grew its holdings in Insulet by 148.2% during the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after buying an additional 63,719 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Insulet by 38.1% during the 3rd quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after buying an additional 12,754 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its holdings in Insulet by 26.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after buying an additional 9,206 shares in the last quarter.

Analyst Ratings Changes

PODD has been the subject of a number of research analyst reports. Barclays cut their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Piper Sandler cut their price objective on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Finally, Oppenheimer lowered their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average target price of $252.04.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.36% of the stock is currently owned by corporate insiders.

Insulet Stock Up 4.7%

Shares of PODD opened at $153.22 on Friday. The company has a market cap of $10.61 billion, a PE ratio of 35.63, a P/E/G ratio of 1.21 and a beta of 1.13. The business has a fifty day moving average of $175.73 and a 200 day moving average of $238.90. Insulet Corporation has a 52-week low of $140.63 and a 52-week high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts expect that Insulet Corporation will post 6.46 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.